KLF9 and diabetic cardiomyopathy: Furthermore, the SGLT-2 inhibitor promoted cardiomyocyte autophagy by blocking miRNA-30d expression, and miRNA-30d negatively regulated KLF9, thereby improving cardiac function in diabetic cardiomyopathy mice (70).